Journal article
68Gallium-DOTATATE positron emission tomography-computed tomography (PET CT) changes management in a majority of patients with neuroendocrine tumors.
- Tierney JF Department of Surgery, Division of Surgical Oncology, Rush University Medical Center, Chicago, IL.
- Kosche C Department of Surgery, Division of Surgical Oncology, Rush University Medical Center, Chicago, IL.
- Schadde E Department of Surgery, Division of Surgical Oncology, Rush University Medical Center, Chicago, IL; Department of Surgery, Division of Transplantation, Rush University Medical Center, Chicago, IL; Department of Surgery, Cantonal Hospital Winterthur, Winterthur, Zurich, Switzerland; University of Zurich, Institute of Physiology, Zurich, Switzerland.
- Ali A Department of Radiology, Division of Nuclear Medicine, Rush University Medical Center, Chicago, IL.
- Virmani S Department of Radiology, Division of Nuclear Medicine, Rush University Medical Center, Chicago, IL.
- Pappas SG Department of Surgery, Division of Surgical Oncology, Rush University Medical Center, Chicago, IL.
- Poirier J Department of Surgery, Division of Surgical Oncology, Rush University Medical Center, Chicago, IL.
- Keutgen XM Department of Surgery, Division of Surgical Oncology, Rush University Medical Center, Chicago, IL. Electronic address: Xavier_Keutgen@rush.edu.
- 2018-11-13
Published in:
- Surgery. - 2019
Clinical Decision-Making
Digestive System Neoplasms
Female
Gallium Radioisotopes
Humans
Lung Neoplasms
Male
Middle Aged
Neuroendocrine Tumors
Organometallic Compounds
Positron Emission Tomography Computed Tomography
Prospective Studies
Thymus Neoplasms
English
BACKGROUND
68Gallium-DOTATATE positron emission tomography-computed tomography (PET CT) has shown superior accuracy in detecting grade 1 and 2 neuroendocrine tumors over previous imaging modalities and was recently included in National Comprehensive Cancer Network guidelines. It remains unclear which patients benefit most from this imaging modality. We therefore reviewed our initial experience with 68Gallium-DOTATATE PET CT to evaluate its usefulness in diagnosing, staging, and surveilling neuroendocrine tumors.
METHODS
Records of patients who underwent 68Gallium-DOTATATE PET CT from March to December 2017 were prospectively evaluated. The primary endpoint was whether 68Gallium-DOTATATE PET CT changes treatment in patients with neuroendocrine tumors. Descriptive statistics, Fisher exact tests, and nested logistic regressions were conducted.
RESULTS
A total of 50 consecutive patients were included. Of these, 41 patients (82%) had a biopsy-proven neuroendocrine tumor at the time of imaging. The remaining 9 patients (18%) had symptoms or biochemistry suggestive of a neuroendocrine tumor with negative cross-sectional imaging. 68Gallium-DOTATATE PET CT changed management in 33 patients (66%). There were 24 patients with intermodality changes in management and 9 patients with intramodality changes in management. Patients with scans performed for staging had a higher likelihood of a change in management (P = .006).
CONCLUSION
Performing 68Gallium-DOTATATE PET CT should be considered for staging and surveillance of neuroendocrine tumors because it is frequently associated with changes in management.
68Gallium-DOTATATE positron emission tomography-computed tomography (PET CT) has shown superior accuracy in detecting grade 1 and 2 neuroendocrine tumors over previous imaging modalities and was recently included in National Comprehensive Cancer Network guidelines. It remains unclear which patients benefit most from this imaging modality. We therefore reviewed our initial experience with 68Gallium-DOTATATE PET CT to evaluate its usefulness in diagnosing, staging, and surveilling neuroendocrine tumors.
METHODS
Records of patients who underwent 68Gallium-DOTATATE PET CT from March to December 2017 were prospectively evaluated. The primary endpoint was whether 68Gallium-DOTATATE PET CT changes treatment in patients with neuroendocrine tumors. Descriptive statistics, Fisher exact tests, and nested logistic regressions were conducted.
RESULTS
A total of 50 consecutive patients were included. Of these, 41 patients (82%) had a biopsy-proven neuroendocrine tumor at the time of imaging. The remaining 9 patients (18%) had symptoms or biochemistry suggestive of a neuroendocrine tumor with negative cross-sectional imaging. 68Gallium-DOTATATE PET CT changed management in 33 patients (66%). There were 24 patients with intermodality changes in management and 9 patients with intramodality changes in management. Patients with scans performed for staging had a higher likelihood of a change in management (P = .006).
CONCLUSION
Performing 68Gallium-DOTATATE PET CT should be considered for staging and surveillance of neuroendocrine tumors because it is frequently associated with changes in management.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1016/j.surg.2018.03.030
- PMID 30415869
- Persistent URL
- https://sonar.ch/global/documents/90969
Statistics
Document views: 12
File downloads: